SEARCH

SEARCH BY CITATION

References

  • 1
    Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 188S203S.
  • 2
    Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic diesease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 401S28S.
  • 3
    Arcelus JI, Caprini JA, Monreal M, Suárez C, González-Fajardo JA. The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. J Vasc Surg 2003; 38: 91622.
  • 4
    Monreal M, López L, Montero M, González-Fajardo JA, Arcelus JI, Caprini JA, for the RIETE Investigators. Venous thromboembolism treatment in the elderly. Findings from the RIETE Registry. Blood 2003; 102: 166a.
  • 5
    Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, Suárez C, Otero R, for the RIETE Investigators. Is the natural history of venous thromboembolism different in surgical and non-surgical patients? Findings from the RIETE Registry. J Thromb Haemost 2004; 2: 18928.
  • 6
    Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 45760.
  • 7
    Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 31528.
  • 8
    Landefeld CS, Cook EF, Flatley M, Wieberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulation therapy. Am J Med 1987; 82: 70313.
  • 9
    Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 14452.
  • 10
    Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringler KA, Antman EM, ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146: 3341.
  • 11
    Pedersen PC, Ostergaard PB, Hedner U, Bergqvist D, Matzsch T. Pharmacokinetics of a low molecular weight heparin, Logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb Res 1991; 61: 47787.
  • 12
    Barrett JS, Hainer JW, Kornhauser DM, Gaskill JL, Hua TA, Sprogel P, Johansen K, van Lier JJ, Knebel W, Pieniaszek HJ Jr. Anticoagulant pharmacodynamics of tinzaparin following 175 IU kg−1 subcutaneous administration to healthy volunteers. Thromb Res 2001; 101: 24354.
  • 13
    Hainer JW, Barrett JS, Assaid CA, Fossler J, Cox DS, Leathers T, Leese PT. Dosing in heavy-weight/obese patients with the LMWH, Tinzaparin: a pharmacodynamic study. Thromb Haemost 2002; 87: 81723.
  • 14
    Davidson BL. Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis. Semin Thromb Hemost 1999; 25 (Suppl 3): 10712.
  • 15
    Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J Thromb Haemost 2004; 2: 54750.
  • 16
    Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004; 2: 5514.
  • 17
    Hirsh J. Laboratory monitoring of low-molecular-weight heparin therapy. J Thromb Haemost 2004; 2: 1003.
  • 18
    Hull RD. Laboratory monitoring of low-molecular-weight heparin therapy. J Thromb Haemost 2004; 2: 10045.
  • 19
    Bachmann F. Laboratory monitoring of low-molecular-weight heparin therapy. J Thromb Haemost 2004; 2: 10056.
  • 20
    Kearon C. Laboratory monitoring of low-molecular-weight heparin therapy. J Thromb Haemost 2004; 2: 10067.
  • 21
    Fiessinger JN. Laboratory monitoring of low-molecular-weight heparin therapy. J Thromb Haemost 2004; 2: 1007.